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  This review paper highlights the use of bi-specific monoclonal antibodies (bsMAb) in 
the diagnostic assays for the early detection of pathogens of human infectious diseases such 
as severe acute respiratory syndrome (SARS), chikungunya (CHIKV), tuberculosis (TB) and 
dengue. Bi-specific monoclonal antibodies (bsMAb) are unique and artificially engineered 
macromolecules with two distinct binding sites, and are capable of binding two different 
antigens non-covalently. However, the traditional methods of diagnosis such as virus or 
bacterial isolation, and PCR amplification are quite expensive and time consuming. Bi-
specific monoclonal antibodies (bsMAb) are versatile, and can increase the specificity and 
sensitivity of detection in the suspected individuals. Therefore, immunodiagnostic assays 
using bsMAb are less expensive, and a large number of clinical samples could be analyzed at 
a faster rate for the detection of pathogens within a stipulated time. This could allow in 
developing a cost effective diagnostic kit, which is very useful particularly in the developing 
countries for the early assessment of the disease outbreak. 
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Bi-specific monoclonal antibodies are 
artificially engineered immunoglobulins with 
two distinct binding specificities (Suresh et al. 
1986a, 1986b; Cao and Suresh, 1998). On the 
other hand monospecific antibodies are the 
naturally occurring major IgG class having 
two identical antigen binding paratopes with 
two identical heavy and light chains (Cao and 
Suresh, 1998). Bispecific monoclonal 
antibodies (bsMAbs) can be produced mainly 
by three methods: 1) Chemically linking two 
antibody molecules, 2) fusion of two different 
hybridomas and 3) using recombinant DNA 
approaches. Bispecific mononclonal 
antibodies have been extensively exploited in 
both diagnostic and therapeutic areas. 
Bispecific antibodies were first generated 37 
years ago by chemical methods (Nisonoff and 
Rivers, 1961; Cao and Suresh, 1998). 
Hybridoma technology opened a wide range 
of applications in fundamental and applied 
immunology (Kohler and Milstein, 1975; 
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Suresh et al. 1986a, 1986b). In 1975, a major 
breakthrough was made by Kohler and 
Milstein (1975) in generating continuous in 
vitro cultures of fused lymphocytes secreting 
antibodies with predetermined specificity. 
Fusion of a normal B cell (plasma cell) with   
myeloma cell (cancerous plasma cell) resulted 
in the generation of a hybrid cell known as 
hybridoma (Kohler and Milstein, 1975; Suresh 
et al. 1986a, 1986b; Cao and Suresh, 1998).  
This hybridoma not only possessed the 
immortal-growth properties of the myeloma 
cell but also secreted an antibody product of 
the B cells. Kohler and Milstein were 
awarded a Nobel prize in 1984 for this work 
(Kohler and Milstein, 1975; Suresh et al. 
1986a, 1986b; Cao and Suresh, 1998).  This 
landmark discovery has revolutionized the 
use of bispecific antibodies (bsMAbs) because 
of the specificity of antigen binding abilities. 
Therefore, bsMAbs have many applications in 
the area of immunodetection, immune-
histochemistry, adioimmunotherapy, adio-
immunodiagnosis, and immunotherapy to 
targeted drug delivery, vaccine development 
and gene therapy (Kohler and Milstein, 1975; 
Suresh et al. 1986a, 1986b; Cao and Suresh, 
1998; Khan et al. 2011, 2012). Furthermore, 
bsMAbs with intrinsic binding sites to any 
two antigens has the capability to form 
uniform, homogeneous and reproducible 
immunoconjugates with one or two entities in 
a predetermined order (Suresh et al. 1986a, 
1986b; Cao and Suresh, 1998). This review 
paper highlights recent diagnostic 
applications of bispecific antibodies in 
immunoswab assay which might play an 
important role in controlling few of the 
following human infectious diseases. 
 
1. SARS (severe acute respiratory 
syndrome). 
Severe acute respiratory syndrome 
(SARS) is a severe form of pneumonia due to 
Corona virus (SARS-CoV) infection, and has 
adapted to human to human transmission 
(Nicholls et al. 2003; Das et al. 2010; Du et al. 
2009). The development of specific diagnostic 
tests against SARS-CoV is an essential step 
for effective treatment of infected patients 
and prevents future SARS outbreaks (Das et 
al. 2010). There are three major diagnostic 
methods are currently available, 1) Viral RNA 
detection using real time reverse transcription 
(RT)-PCR (Jiang et al. 2004; Poon et al. 2004), 
2) Antibody detection (Chan et al. 2004; Li et 
al. 2005), 3) Antigen detection (Che et al. 2004; 
Li et al. 2005). The most predominant SARS-
CoV virus derived protein throughout the 
infection is the nucleocapsid protein (NP) 
(Hiscox et al. 1995).    
In our laboratory, five monoclonal 
antibodies (bsMAbs) against recombinant 
nucleocapsid protein (NP) of severe acute 
respiratory syndrome (SARS) causing 
coronovirus (CoV) were developed by 
hybridoma technology (Das et al. 2010). A 
highly sensitive, rapid and simple bsMAb-
based immunoswab assay was also 
developed in our laboratory for early 
detection of SARS-CoV (Kammila et al. 2008; 
Suresh et al. 2008; Bhatnagar et al. 2008; Das et 
al. 2010). In the immunoswab assay, easy-to-
use swabs were first coated with anti-SARS-
CoV monoclonal antibody to capture NP in 
the test sample followed by detection with 
bsMAb (Kammila et al. 2008; Das et al. 2010). 
The immunoswab assay showed NP 
detection limits of 10 pg/mL (1 pg/swab) in 
saline, 20–200 pg/mL (1–10 pg/swab) in pig 
nasopharyngeal aspirate and 500 pg/mL (25 
pg/swab) in rabbit serum.  This assay was 
completed within a period of approximately 
45 minutes, which make it a rapid test for 
SARS diagnosis (Kammila et al. 2008). In 
another development, an ultrasensitive 
ELISA using mouse monoclonal IgG 
combined with chicken polyclonal IgY 
antibody for SARS virus infection. The 
immunoassay method of detecting SARS-
CoV NP antigen could be used as a cost 
effective diagnostic kit for checking the SARS 
suspected individuals.        
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2) Dengue 
  Dengue is one of the viral diseases 
recorded throughout the world. The 
mosquito which is responsible for 
transmission of dengue virus between 
humans and monkeys is known as Aedes 
aegypti (Murrell et al. 2011 Schieffelin et al. 
2010; Shrivastava et al. 2011; Malabadi et al.  
2010, 2011; Monath, 1994). Dengue virus is a 
member of the genus Flavivirus (family 
Flaviviridae) (Halstead, 1988, 1989; Murrell et 
al. 2011). In many cases of infected individual, 
dengue fever (DF) is appeared as the dengue 
hemorrhagic fever (DHF) or dengue shock 
syndrome (DSS) (Halstead, 1989; Murrell et al. 
2011). Dengue virus is endemic and 
significantly causing the death of many 
children (Murrell et al. 2011; Shrivastava et al. 
2011; WHO, 2009, 2010; Simasathien and 
Watanaveeradej, 2005; Gubler and Meltzer, 
1999). Till today, dengue disease is not under 
control and effective immunization may 
provide protection for controlling dengue 
infections (Murrell et al. 2011; Shrivastava et 
al. 2011; Malabadi et al. 2011; Schieffelin et al. 
2010). Therefore, potential vaccine for dengue 
has been challenging, and there are many 
problems associated with the development of 
dengue vaccine (Holmes and Twiddy, 2003; 
Rico-Hesse, 1990; Murrell et al. 2011; 
Malabadi et al. 2011). Long duration 
immunity to only one serotype is observed in 
many infected individuals. On the other hand 
dengue infected individuals showed short 
duration immunity to the other serotypes 
(Sabin, 1989; Schieffelin et al. 2010; Malabadi 
et al. 2011). One of the major problems is that 
short duration immunity is lost after 3-4 
months, and individual has no immunity to 
the other three dengue serotypes (Murrell et 
al. 2011; Shrivastava et al. 2011).   
Currently there is no diagnostic assay 
available for the detection of dengue virus 
infection at the acute or early stages. Ganguly 
and co workers in our laboratory have 
developed a novel, highly sensitive 
immunodiagnostic assay for the detection of 
dengue virus using bsMAb. The assay is 
highly specific and easy to perform since it 
does not require any technical expertise or 
sophisticated instruments. The general format 
of the immunodiagnostic assay involves 
coating of dengue virus antigen-specific 
monoclonal antibody as the capture antibody 
on calcium alginate tipped swabs with 
aluminum/or plastic shafts as per previously 
published protocol (Tang et al. 2004).  
  
3) Chikungunya 
Chikungunya is another viral disease, 
which was reported for the first time in 
Tanzania (Robinson, 1955; Muthumani et al. 
2008). The epidemic cycle of chikungunya is 
similar to those of dengue and urban yellow 
fever. Chikungunya virus (CHIKV) is a 
mosquito-borne alpha virus belongs to the 
family of Togaviridae (Strauss and Strauss, 
1994; Tiwari et al. 2009; Akahata et al. 2010). 
Geographically, chikungunya virus (CHIKV) 
is distributed in Africa, India and South East 
Asia (Mavalankar et al. 2007; Tiwari et al. 
2009). The symptoms of the diseases involves 
fever, headache, rash, nausea, vomiting, 
myalgia, and arthralgia/arthritis (Simon et al. 
2008; Powers and Logue, 2007; Akahata et al. 
2010). The severity of the disease is 
characterized by the neurological 
manifestations such as acute limb weakness, 
and joint pain with a fatal haemorrhagic 
condition (Muthumani et al. 2008; Mohan et 
al. 2010). Chikungunya was reported as a 
major epidemic disease during 2004-2007 in 
Indian Ocean islands and India (Paramasivan 
et al. 2009; Tiwari et al. 2009; Mohan et al. 
2010; Gardner et al. 2010). No licensed vaccine 
or effective drug is available in the market 
throughout the world for chikungunya 
disease. However, the expression level of the 
CHIKV protein is very low in mammalian or 
bacterial or insect cells. Furthermore, the 
expressed protein is easily degraded.  
Therefore, there is an urgent need for the 
development of diagnostic assay for the early 
detection of the disease in the infected 
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individuals. However, current methods of 
early detection of chikungunya antigen in the 
infected individuals using PCR amplification 
are very expensive. The PCR methods involve 
use of technically trained man power, costly 
chemicals, and sophisticated instruments for 
the assay which the developing countries can 
not afford. Till today, there are no reports of 
immunoswab assays as the diagnostic 
approach for chikungunya. Therefore, a 
sensitive, in expensive diagnostic test using 
immunoswab assay could be developed for 
the detection of early stages of the 
chikungunya viral infection. This 
immunoswab assay is simple, reliable, fast, 
and will save of money.   
 
4) Tuberculosis (TB) 
 The gram positive bacterium which is 
a causative agent for tuberculosis is known as 
Mycobacterium tuberculosis (Sarkar and Suresh, 
2011, Chaudhary et al. 2010, Gennaro, 2000). 
Tuberculosis (TB) is still a major health 
problem in many countries throughout the 
world. M. bovis Bacillus Calmette-Guerin (BCG) 
is the only live bacterial vaccine in use that 
has shown no major side-effects. However, 
BCG vaccination is ineffective against adult 
pulmonary TB, and therefore, there is an 
urgent need for potential vaccines is a high 
priority. Furthermore, HIV patients and 
multi-drug resistant mycobacterium strains 
have contributed to the re-emergence of TB 
(Sarkar et al. 2012). The major problem is that 
there is no specific diagnostic approach to 
find out the early stages of TB. Unfortunately, 
the false negative results of current TB 
diagnostic test such as sputum smear 
microscopy (SSM) are not reliable (Sarkar et al. 
2012, Sarkar and Suresh, 2011, Chaudhary et 
al. 2010, Gennaro, 2000).  In addition, clinical 
symptoms and results of chest x-rays are 
nonspecific (Sarkar et al. 2012). PCR based 
diagnosis is very expensive, which needs 
costly sophisticated instrumentation and time 
consuming too. Another simple method is the 
culture method for the detection of TB. The 
major drawback of this method is a time 
consuming since it takes 2-7 weeks to obtain 
results. Therefore, early diagnosis is very 
important since TB is a highly contagious 
disease at the early stages of development. 
Therefore, our laboratory has developed a 
novel, and highly sensitive 
immunodiagnostic assay for the detection of 
M. tuberculosis using bsMAb (Sarkar et al. 
2012). TB diagnostic test was developed as 
per Sarkar et al. (2012). The assay is highly 
specific, sensitive, very fast to get results, and 
very less expensive.   
 Therefore, the use of bsMAb in the 
immunodiagnostic assays plays an important 
role in the modern medicine. This method of 
diagnostic approach is very simple, rapid and 
cost effective. Early diagnosis always helps 
the patients in controlling the spread of 
disease at the right time. It will also help the 
physicians for recommending the proper 
medication for controlling the disease in the 
infected individual. 
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